全文获取类型
收费全文 | 132691篇 |
免费 | 45045篇 |
国内免费 | 668篇 |
专业分类
耳鼻咽喉 | 1940篇 |
儿科学 | 5665篇 |
妇产科学 | 805篇 |
基础医学 | 27306篇 |
口腔科学 | 7032篇 |
临床医学 | 15422篇 |
内科学 | 30414篇 |
皮肤病学 | 4688篇 |
神经病学 | 19637篇 |
特种医学 | 6237篇 |
外国民族医学 | 4篇 |
外科学 | 17071篇 |
综合类 | 2718篇 |
现状与发展 | 5篇 |
一般理论 | 10篇 |
预防医学 | 9000篇 |
眼科学 | 1577篇 |
药学 | 12261篇 |
2篇 | |
中国医学 | 2372篇 |
肿瘤学 | 14238篇 |
出版年
2024年 | 42篇 |
2023年 | 551篇 |
2022年 | 1159篇 |
2021年 | 2680篇 |
2020年 | 6846篇 |
2019年 | 12499篇 |
2018年 | 11953篇 |
2017年 | 13072篇 |
2016年 | 12025篇 |
2015年 | 12012篇 |
2014年 | 12310篇 |
2013年 | 12429篇 |
2012年 | 11481篇 |
2011年 | 11615篇 |
2010年 | 10169篇 |
2009年 | 6445篇 |
2008年 | 6989篇 |
2007年 | 5244篇 |
2006年 | 4857篇 |
2005年 | 4652篇 |
2004年 | 4462篇 |
2003年 | 3961篇 |
2002年 | 3636篇 |
2001年 | 2784篇 |
2000年 | 1623篇 |
1999年 | 501篇 |
1998年 | 226篇 |
1997年 | 183篇 |
1996年 | 175篇 |
1995年 | 142篇 |
1994年 | 102篇 |
1993年 | 97篇 |
1992年 | 80篇 |
1991年 | 92篇 |
1990年 | 67篇 |
1989年 | 54篇 |
1988年 | 46篇 |
1987年 | 39篇 |
1985年 | 123篇 |
1984年 | 126篇 |
1983年 | 112篇 |
1982年 | 120篇 |
1981年 | 105篇 |
1980年 | 87篇 |
1979年 | 110篇 |
1978年 | 64篇 |
1977年 | 53篇 |
1976年 | 44篇 |
1975年 | 40篇 |
1973年 | 34篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
81.
82.
83.
84.
目的 分析HBV患者YKL-40、CA19-9、GP73水平差异及与患者病情轻重程度的相关性,探讨HBV患者病情的判定指标。方法 选取2015年5月—2018年5月收治的100例HBV患者,其中慢性HBV感染组40例、慢性乙型肝炎组36例、HBV相关肝硬化组24例,同期选择我院健康体检的健康者50例作为健康对照组;检测患者血中YKL-40、CA19-9、GP73水平;分析HBV感染患者血清YKL-40、CA19-9、GP73水平与病情轻重程度的相关性。结果 慢性HBV感染、慢性乙型肝炎及HBV相关肝硬化患者血中YKL-40水平分别为(36.38±4.19)ng/mL 、(49.02±4.32)ng/mL、(65.14±5.21)ng/mL ,CA19-9分别为(12.03±1.03)KU/L、(13.84±0.98)KU/L、(16.94±0.81)KU/L,GP73分别为(47.22±5.38)ng/mL 、(98.53±10.24)ng/mL 、(229.85±12.19)ng/mL,均明显高于对照组的(28.19±3.27)ng/mL 、(7.34±0.92)KU/L 、(30.93±3.89)ng/mL,均P=0.000 0。随着慢性HBV感染者、慢性乙型肝炎患者和不同HBV相关肝硬化患者肝脏炎症及纤维化程度加重,患者血中YKL-40、CA19-9和GP73也随之显著增加,均P=0.000 0;YKL-40、CA19-9和GP73均是影响HBV感染患者体内炎症坏死及肝脏纤维化的独立性影响因素,差异有统计学意义(P<0.05)。结论 HBV感染患者血清中YKL-40、CA19-9、GP73水平是HBV感染患者病情轻重程度的独立性影响因素。 相似文献
85.
86.
87.
Erika Cecon Anna Ivanova Marine Luka Florence Gbahou Anne Friederich Jean‐Luc Guillaume Patrick Keller Klaus Knoch Raise Ahmad Philippe Delagrange Michele Solimena Ralf Jockers 《Journal of pineal research》2019,66(2)
Melatonin receptors play important roles in the regulation of circadian and seasonal rhythms, sleep, retinal functions, the immune system, depression, and type 2 diabetes development. Melatonin receptors are approved drug targets for insomnia, non‐24‐hour sleep‐wake disorders, and major depressive disorders. In mammals, two melatonin receptors (MTRs) exist, MT1 and MT2, belonging to the G protein‐coupled receptor (GPCR) superfamily. Similar to most other GPCRs, reliable antibodies recognizing melatonin receptors proved to be difficult to obtain. Here, we describe the development of the first monoclonal antibodies (mABs) for mouse MT1 and MT2. Purified antibodies were extensively characterized for specific reactivity with mouse, rat, and human MT1 and MT2 by Western blot, immunoprecipitation, immunofluorescence, and proximity ligation assay. Several mABs were specific for either mouse MT1 or MT2. None of the mABs cross‐reacted with rat MTRs, and some were able to react with human MTRs. The specificity of the selected mABs was validated by immunofluorescence microscopy in three established locations (retina, suprachiasmatic nuclei, pituitary gland) for MTR expression in mice using MTR‐KO mice as control. MT2 expression was not detected in mouse insulinoma MIN6 cells or pancreatic beta‐cells. Collectively, we report the first monoclonal antibodies recognizing recombinant and native mouse melatonin receptors that will be valuable tools for future studies. 相似文献
88.
89.
90.
Mt D. Dbrssy Chockalingam Ramanathan Danesh Ashouri Vajari Yixin Tong Thomas Schlaepfer Volker A. Coenen 《The European journal of neuroscience》2021,53(1):89-113
Deep brain stimulation (DBS) in psychiatric illnesses has been clinically tested over the past 20 years. The clinical application of DBS to the superolateral branch of the medial forebrain bundle in treatment‐resistant depressed patients—one of several targets under investigation—has shown to be promising in a number of uncontrolled open label trials. However, there are remain numerous questions that need to be investigated to understand and optimize the clinical use of DBS in depression, including, for example, the relationship between the symptoms, the biological substrates/projections and the stimulation itself. In the context of precision and customized medicine, the current paper focuses on clinical and experimental research of medial forebrain bundle DBS in depression or in animal models of depression, demonstrating how clinical and scientific progress can work in tandem to test the therapeutic value and investigate the mechanisms of this experimental treatment. As one of the hypotheses is that depression engenders changes in the reward and motivational networks, the review looks at how stimulation of the medial forebrain bundle impacts the dopaminergic system. 相似文献